Nalmefene: a new approach to the treatment of alcohol dependence

Abstract

Reduction of alcohol consumption is not yet a widely accepted treatment objective for alcohol-dependent patients, as abstinence is often considered to be the only possible objective in this situation. However, various studies have demonstrated the value of proposing these two options to such patients. Firstly, reduction of alcohol consumption very significantly reduces the risk of alcohol-related damage, and also modifies the patient’s and the doctor’s perception of the disease, resulting in improved access to care and better patient adherence with the proposed treatment objective and consequently better clinical results. Recent studies have shown that some medicinal products can help patients reduce their alcohol consumption. One such product, nalmefene, has been granted European marketing authorization and is now being released onto the market in various countries. The ESENSE 1 and 2 studies in alcohol-dependent patients showed that, in combination with BRENDA, a psychosocial intervention focusing on reinforcement of motivation and treatment adherence, nalmefene significantly reduced the number of heavy drinking days and mean daily total alcohol consumption versus placebo. This reduction was more marked in the marketing authorization target population, ie, patients with a high or very high drinking risk level according to World Health Organization criteria. Another original feature of this molecule is that it can be used as needed if the patient perceives a risk of drinking, which is a more flexible approach and more likely to ensure the patient’s active involvement in the treatment of his/her disease. This molecule opens up interesting and original therapeutic prospects in the treatment of alcohol dependence.

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

“…Non-selective opioid receptor antagonist alcoholism in a double-blind study (Grant et al, 2006) and PG (Paille and Martini, 2014) GABAergic system Topiramate GABA A agonist ICD (Bermejo, 2008) behavioral addictions: PG, binge eating. .…”

“…Naltrexone has been shown to be effective in reducing the abuse of nicotine (King et al, 2013), alcohol (Morgenstern et al, 2012), heroin and amphetamine (Adi et al, 2007;Tiihonen et al, 2012), and to treat PG (Grant et al, 2008), as well as improving altered sexual behavior (Bostwick and Bucci, 2008;Raymond et al, 2010). Nalmefene, an opioid receptor antagonist similar in both structure and activity to naltrexone, is also effective in alcoholism and PG in the general population (Grant et al, 2006;Paille and Martini, 2014).…”

Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study

“…Both are MOR antagonists and the latter is also a partial agonist of KOR (Paille and Martini, 2014;Wackernah et al, 2014). The efficacy of naltrexone for the treatment of alcoholism is only modest (Spanagel and Kiefer, 2008).…”

Alcoholism: Success of Long–Term Treatment - a Systematic Review

“…Respondents were checked after the intensive treatment by the aftercare telephone monitoring. The patients were asked questions about abstinence/ sented as a new medical means to reduce the desire for alcohol but for now there is not enough experience of what will be its lasting effect (12).…”